PBLS vs HP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PBLS · Parabilis Medicines$28.53 ▲ 2.33%
HP · Helmerich & Payne$35.22 ▲ 1.56%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PBLS -9.7%
- HP -10.0%
Head to head
| Metric | PBLS | HP |
|---|---|---|
| Price | $28.53 | $35.22 |
| Change today | ▲ 2.33% | ▲ 1.56% |
| Market cap | $3.52B | $3.52B |
| Return, 3 months | -20.2% | -15.4% |
| Return, year to date | – | +25.2% |
| Return, 1 year | – | +38.4% |
| P/E (TTM) | – | – |
| P/B | 3.4 | 1.4 |
| P/E percentile vs own 5y | 80th | 14th |
| Dividend yield | – | 2.84% |
| Revenue growth (YoY, latest qtr) | – | -0.6% |
| Net profit growth (YoY) | -50.7% | +148.3% |
| Gross margin | – | 13.5% |
| Operating margin | -117,335.8% | 3.0% |
| Net margin | -156,531.8% | -3.5% |
| Return on equity | -22.1% | -5.2% |
| Analyst target vs. price | +46.3% | +30.9% |
| Analyst buy share | 100% | 55% |
| RSI (14) | 49 | 37 |
| 30-day volatility | 83.3% | 50.1% |
| Max drawdown, 1 year | -45.5% | -27.2% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PBLS is the largest of the group by market value.
- HP keeps the most profit per dollar of sales.
- HP has been the calmest stock over the last 30 days.